Endobronchial Valve as Treatment of Emphysema Compared with Standard Medical Care: an Evidence-based Case Report by Tenda, Eric D & Yakub, Abraham
SPECIAL  ARTICLE
70 Acta Medica Indonesiana - The Indonesian Journal of Internal Medicine
Endobronchial Valve as Treatment of Emphysema Compared 
with Standard Medical Care: an Evidence-based Case Report
Eric D. Tenda, Abraham Yakub
Department of Internal Medicine, Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, 
Jakarta, Indonesia.
Corresponding Author:
Eric D. Tenda, MD. Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of 
Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital. Jl. Diponegoro 71, Jakarta 10430, Indonesia. 
email: ericdanieltenda@yahoo.com.
ABSTRAK
Tujuan: menilai efektivitas penggunaan endobronchial valve sebagai tatalaksana pasien dengan emfisema 
dibandingkan dengan tatalaksana medikal. Metode: pencarian kepustakaan mengenai perbandingan pengunaan 
endobronchial valve dan tatalaksana medikal pada emfisema di PubMed database. Kualitas dari kepustakaan 
yang didapat dinilai dengan menggunakan daftar tilik dari Center of Evidence-Based Medicine, University of 
Oxford. Hasil: dua randomized controlled trial (RCT) didapatkan dari pencarian kepustakaan. Didapatkan 
bahwa terapi dengan endobronchial valve meningkatkan kualitas pasien emfisema derajat sedang hingga sangat 
berat secara bermakna dibandingkan dengan tatalaksana medikal. Akan tetapi, peningkatan bermakna tersebut 
terjadi pada pasien emfisema dengan heterogenitas tinggi, fissura interlobar lengkap, dan ketiadaan ventilasi 
kolateral. Kesimpulan: endobronchial valve merupakan terapi yang lebih efektif pada pasien emfisema dengan 
keheterogenan tinggi, fissura interlobar lengkap, dan ketiadaan ventilasi kolateral. Pemeriksaan dengan High 
Resolution CT-scan (HRCT) harus dilakukan untuk memutuskan apakah terapi dengan endobronchial valve 
cocok untuk dilakukan pada seorang pasien dengan emfisema.
Kata kunci: endobronchial valve, talalaksana medikal, emfisema.
ABSTRACT
Aim: to determine the effectiveness of endobronchial valve placement as treatment of emphysema compared 
to medical care. Methods: literature searching regarding comparison of endobronchial valve and medical 
care as treatment of emphysema on PubMed database. The quality of the literatures found was appraised by 
using critical appraisal sheet from Center of Evidence-Based Medicine, University of Oxford. Results: two 
randomized controlled trials (RCT) were obtained from literature searching. It was revealed that endobronchial 
valve placement improved quality of patients with moderate to very severe as compared to medical treatment 
significantly. However, these significant improvements occurred in patients with high heterogeneity emphysema, 
complete interlobar fissure, and absence of collateral ventilation. Conclusion: endobronchial valve placement 
was a more effective treatment in patients with high heterogeneity emphysema, complete interlobar fissure, and 
absence of collateral ventilation. Assessment by using High Resolution CT-scan (HRCT) must be conducted 
prior to valve placement to determine suitability of this approach in emphysema patients.
Keywords: endobronchial valve, medical care, emphysema.
Vol 48 • Number 1 • January 2016                                               Endobronchial valve as a treatment of emphysema
INTRODUCTION
Emphysema one of the manifestation of 
chronic obstructive pulmonary disease (COPD)
characterized by airway walls destruction causing 
increased size of distal airways further than 
terminal bronchioles, leads it to parenchymal 
destruction.1,2 COPD has become a global burden 
with about 65 million people predicted to suffer 
from moderate to severe COPD.3 Furthermore, 
this condition also accounted for about 3 million 
deaths in 2005 worldwide.3 In Indonesia, it was 
estimated that the prevalence of COPD was 3.7% 
according to Result of National Basic Health 
Research (RISKESDAS) 2013.4
Medical care of emphysema involves use of 
bronchodilators, anti-cholinergics, corticosteroids, 
or a combination of bronchodilator-corticosteroid.1 
Another option directed for severe emphysema 
treatment is endobronchial valve placement.1 
Endobronchial valve is a one-way valve placed at 
the targeted lobe through a bronchoscope.5 This 
one-way valve prevents inspired air entering while 
allowing exhaled air to pass leading to atelectasis 
in targeted lobe.5
CLINICAL QUESTION
A 56 years old man was diagnosed with 
emphysema 4 years ago. He had two exacerbations 
this year which occurred two and nine months ago. 
His last post-bronchodilator spirometry results 
after the second exacerbation were FEV1/FVC 
55% and FEV1 35% of predicted value. Regular 
medications he received consisted of combination 
of inhaled long β2 agonist + corticosteroid 
(salmeterol 50 μg + fluticasone propionate 500 
μg) twice a day and long acting anticholinergic 
(tiotropium bromide 18 μg) once a day. We aim to 
determine whether endobronchial valve placement 
is more effective than medical care and suitability 
of this approach for this patient.
In pat ients  with emphysema,  does 
endobronchial valve placement result in better 
outcomes compared to medical care?
METHODS
The eligible studies were searched from 
PubMed database on 26th December 2015. The 
limitation criteria of literature searching were: 
(1) Therapy studies regarding comparison of 
endobronchial valve and medical care exclusively 
in patients with emphysema, (2) Exclusion of 
review articles, (3) Studies published in English 
or Indonesian. The keywords used for literature 
searching were: endobronchial valve, medical 
care, and emphysema. Literature searching was 
conducted through combination of these three 
keywords which used Boolean operator “AND”. 
The selected studies were then appraised using 
Center of Evidence-Based Medicine, University 
of Oxford critical appraisal sheet for therapy study 
or systematic review to check their validity.6,7
RESULTS
From the literature searching, two studies 
were found (Figure 1). These eligible studies were 
critically appraised using Center of Evidence-
Based Medicine, University of Oxford critical 
appraisal sheet for therapy study (Table 1).6 The 
summary of each study was described in Table 2.
In the study conducted by Sciurba et al8, 
standard medical care was defined according 
to the Endobronchial Valve for Emphysema 
Palliation Trial (VENT) design.9-10 In VENT, 
standard medical care was based on GOLD 2001 
guidelines.11 Study conducted by Klooster et al 
(2015) defined standard medical care according 
to GOLD 2006 guideline.9,12
Keywords combination: “endobronchial valve”
AND “medical care” AND “emphysema”
PubMed database: 9 studies
Exclude
 Not in English/ Indonesian: 1
 Not/not fully compared with standard
medical care: 2
 Not study regarding therapy result: 2
 Not study of endobronchial valve in
emphysema: 2
2 studies
2 studies included
Critical appraisal
Figure 1. Flow chart of literature searching process.
DISCUSSION
From literature searching, only two studies 
compared the treatment of emphysema using 
endobronchial valve to medical care were found. 
These two studies were randomized controlled 
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Table 1. Critical appraisal of two randomized controlled studies
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Sciurba, et al.8 2010 321 RCT + + + + - 2
Klooster, et al.9 2015 68 RCT + + + + -* 2
N: number of participants; RCT: randomized controlled trial; *blinding was conducted for outcome assessors only; +: level 
of evidence as determined by Center of Evidence-Based Medicine, University of Oxford.10
Table 2. Summary of two randomized controlled trials included
Study Patient Characteristic Results Complications
Sciurba, et al.8 Age: 40-75 years old; 
FEV1: 15-45% predicted 
value; TLC >100% 
predicted value;  RV 
>150% predicted value
3.8 valves/patient were placed on average Major adverse events in 90 
days: Two deaths occurred 
in endobronchial valve group 
but not significantly different 
compared to medical care 
group (p-value=1.00)
BMI ≤31.1 kg/m2 
(male), ≤32.3 kg/m2 
(female); PaCO2 <50 
mmHg, PaO2 >45 
mmHg; 6-minute walk 
test ≥140 meter.
6 months follow up period:
Improvement of FEV1 (%): 4.3% 
(endobronchial valve) vs -2.5% (medical 
care), p-value=0.005
Patients with 
heterogeneous 
emphysema as revealed 
by HRCT.
Improvement of 6-minute walk test (meter): 
9.3 meter (endobronchial valve) vs -10.7 
meter (medical care), p-value=0.02
No significant difference in 
major adverse events  such 
as respiratory failure, massive 
hemoptysis,  pneumothorax 
>7 days, and others between 
endobronchial valve group 
and medical care group 
(p-value>0.05)
No significant 
difference of baseline 
characteristics between 
endobronchial valve and 
medical care group
Improvement of FEV1 (% difference: 
10.7%, p-value=0.004) and 6-min walk 
test (distance difference: 12 meter, 
¬p-value=0.002) in patients with high 
heterogeneity* was significantly higher in 
endobronchial valve compared to medical 
care but not in low heterogeneity patients 
(% FEV1 improvement difference: 2.5%, 
p-value=0.38; 6-min walk test difference: 
-1.0 meter, p-value=0.80).
Improvement of in patients with complete 
fissure† was significantly higher in 
endobronchial valve compared to 
medical care FEV1 (% difference: 16.2%, 
p-value<0.001) but not in incomplete 
fissure patients  (% difference: 2.0%, 
p-value=0.51)
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trials conducted by Sciurba et al8 and Klooster 
et al9, respectively. Three point eight until four 
valves were placed for every patient on average.
The characteristics of recruited patients 
between these two studies were almost similar. 
Subjects in the study conducted by Sciurba et 
al8 included patients with severe to very severe 
emphysema while Klooster et al9 also included 
patients with moderate emphysema.1 Both 
studies revealed that improvement of the FEV1 
and 6-minute walk test was significantly higher 
in the endobronchial valve group at 6 months 
follow up period for patients with moderate 
to very severe emphysema.8,9 Furthermore, 
occurrence of adverse events in endobronchial 
valve group was similar compared to medical 
treatment group at 90 days and 6 months follow 
up.8,9 Mortality occurrence was found in the 
endobronchial valve group but not statistically 
difference compared to the medical care group.8,9 
Interestingly, there were three important features 
that must be considered to determine suitability 
for endobronchial valve placement. These 
three features were emphysema heterogeneity, 
interlobar fissure integrity, and absence of 
collateral ventilation.8,9
According to quantitative densitometry from 
HRCT, emphysema was determined as presence 
of density value which was less than -910 HU 
(Hounsfield Units).13 Sciurba et al8 found that 
improvement of both FEV1 and 6-minute 
walk test from endobronchial valve placement 
occurred in subjects with high heterogeneity 
emphysema.8 In this study, high heterogeneity 
was defined as percentage of pixels less than 
-910 HU between targeted lobe and its adjacent 
lobe was more than 15%.8 This indicated 
that heterogeneity of emphysema determined 
effectiveness of endobronchial valve placement 
hence heterogeneity assessment by HRCT prior 
to valve placement was crucial.
The second important feature was interlobar 
fissure integrity. Sciurba, et al defined an 
interlobar fissure to be complete if presence 
of fissure was more than 90% on at least one 
axis in thin slice HRCT.8 Incomplete interlobar 
fissure signified presence of collateral ventilation 
which passed across this incomplete fissure.14 
Collateral ventilation, the third important feature, 
was described as ventilation that occurs through 
Table 2. Summary of two randomized controlled trials included
Study Patient Characteristic Results Complications
Klooster, et al.9 Age >35 years old; FEV1 
post-bronchodilator 
<60% predicted; TLC 
>100% predicted value; 
RV >150% predicted 
value; mMRC scale >1
4 valves/patient were placed on average Serious adverse events 
in 6 months follow up 
period: One death found in 
endobronchial valve group 
but not significantly different 
compared to medical care 
group (p-value=1.00)
Patients with complete 
or near complete fissure 
as revealed by HRCT
6 months follow up period: Improvement 
of FEV1 (%): 20.9% (endobronchial valve) vs 
3.1% (medical care), p-value=0.002
Absence of collateral 
ventilation as assessed 
by using Chartis system 
(Pulmonx)
Improvement of FVC (%): 18.3% 
(endobronchial valve) vs 4.0% (medical care), 
p-value=0.005
Incidence of pneumothorax 
was higher in endobronchial 
valve group (18% vs 0%, 
p-value=0.02)
No significant 
difference of baseline 
characteristics between 
endobronchial valve and 
medical care group
Improvement of 6-minute walk test (meter): 
60 meter (endobronchial valve) vs -14.0 
meter (medical care), p-value<0.001
FEV1: forced expiratory volume in 1 second; HRCT: high resolution CT-scan; mMRC scale: Modified Medical Research 
Council scale (range: 0-4, higher value represented more uncompromising dyspnea); RV: residual volume; TLC: total lung 
capacity; *high heterogeneity was described percentage of emphysema heterogeneity >15%. Percentage of emphysema 
heterogeneity was counted as proportion of pixels < -910 HU between targeted lobe and ipsilateral adjacent targeted lobe 
as shown by HRCT; †complete fissure was described as present of >90% fissure on thin slice HRCT on at least one axis.
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passages which bypass the normal airways.15 
Sciurba et al8 found that improvement of 
FEV1 was significantly higher in subjects with 
complete interlobar fissure but not in incomplete 
interlobar fissure.8
Klooster et al9 determined the presence of 
collateral ventilation by using Chartis system 
(Pulmonx). From their study which only 
recruited patients with absence of interlobar 
collateral ventilation, improvement of FEV1, 
FVC, and 6-min walk test were significantly 
higher in endobronchial valve group.9 In this 
system, an inflated balloon was placed on 
target airway through catheter hence expired air 
would pass only from the catheter.16 Absence 
of collateral ventilation would be marked by 
continuous decrease of expired air.16 It was 
reported that Chartis system (Pulmonx) had 
similar diagnostic performance as compared to 
HRCT fissure analysis.17 This system might be 
used as an alternative approach instead of HRCT 
in determining presence of collateral ventilation. 
As for the patient in the case illustration, 
treatment by endobronchial valve might be 
considered. Assessment by HRCT should 
be conducted prior to valve placement to 
determine emphysema heterogeneity and fissure 
completeness. Endobronchial valve placement 
would be suitable if the HRCT result reveals 
complete fissure which indicates absence of 
collateral ventilation and high heterogeneity 
emphysema. Since we did not find studies 
that compared use of medical care after valve 
placement and valve placement only, we could 
not determine whether the use of medical 
treatment gives additional benefits after valve 
placement.
Currently, the endobronchial valve is not 
available in Indonesia. However, the possibility 
of using this novel approach in the future 
should be considered by physicians due to its 
high efficacy in managing severe emphysema. 
Regarding the cost of treatment, Pietzsch et 
al18 mentioned that it would cost EUR 9,581 
for average 3.08 valves placement for every 
procedure. This study also predicted that 
endobronchial valve placement would increase 
quality-adjusted life year (QALY) by 0.41 point 
with an extra cost of EUR 10,425 over 10 years 
as compared to medical treatment.18
CONCLUSION
Endobronchial valve placement is more 
effective compared to medical care in patients 
with high heterogeneity emphysema, complete 
fissure, and absence of collateral ventilation. 
Assessment by HRCT should be conducted prior 
to valve placement to determine suitability for 
valve placement. Further studies are needed to 
determine whether use of medical care after valve 
placement gives additional benefits.
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